Medpace Holdings Inc vs National Energy Services Reunited Corp Ordinary Shares — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.02B), while National Energy Services Reunited Corp Ordinary Shares trades at $19.5 (market cap $2.12B). The key difference: Medpace Holdings Inc is far larger — about 8× National Energy Services Reunited Corp Ordinary Shares's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, National Energy Services Reunited Corp Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and National Energy Services Reunited Corp Ordinary Shares for 0 Days on average.
| MEDP | NESR | |
|---|---|---|
Market Cap | $17.02B | $2.12B |
Volume | 155,250 | 3,257,316 |
Sector | Health | Energy |
52-Week High | $630.19 | $36.31 |
52-Week Low | $393.42 | $10.41 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.63B | $2.24B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $609.89, down 1.64% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent news highlights CEO stock sales and institutional position adjustments, while Q3 2026 results are expected October 21, 2026.
MEDP offers growth potential with a consensus price target of $620.44 (1.7% upside), supported by projected 2026 revenue growth to $2.8B. Risks include high valuation multiples (P/E 35.82) and insider selling. Analyst sentiment is cautious with 78.95% hold ratings, suggesting limited near-term catalysts.
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →